Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor

Kristina Hoffmann, Younis Baqi, María Sol Morena, Markus Glänzel, Christa E. Müller, Ivar Von Kügelgen

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The P2Y12 receptor plays a crucial role in platelet aggregation. In the present study, we analyzed the properties of non-nucleotide antagonists at the recombinant human P2Y12 receptor and searched for amino acids involved in the molecular interaction. Receptor function was assessed by measuring the cAMP response element (CRE)-directed luciferase expression in Chinese hamster ovary cells. The cellular cAMP production was accelerated by forskolin; 2-methylthio-ADP was used to activate the wild-type P2Y12 receptor or mutant constructs. 2-Methylthio-ADP inhibited the CRE-dependent luciferase expression with an IC50 value of approximately 1 nM. The anthraquinone derivative reactive blue 2 used at increasing concentrations shifted the concentration-response curve of 2-methylthio-ADP to the right in a manner compatible with competitive antagonism (pA2 value, 7.4). Its analog, 1-amino-4-[4-phenylamino-3-sulfophenylamino]-9,10-dioxo-9,10- dihydroanthracene-2-sulfonate (PSB-0739), showed a markedly higher antagonistic potency with a pA2 value of 9.8. In cells expressing the R256A-mutant receptor, the potencies of both reactive blue 2 (apparent pKB, 5.9) and PSB-0739 (apparent pKB, 9.1) were decreased. The same was true for the pure reactive blue 2 meta- and para-isomers and for the ortho-isomer cibacron blue 3GA. In contrast, the analog, 1-amino-4-[4-anilino-phenylamino]-9, 10-dioxo-9,10-dihydroanthracene-2-sulfonate, lacking a sulfonic acid residue at ring D (PSB-0826), showed similar pKB values at wild-type (8.4) and R256A-mutant receptors (8.3). In summary, the results demonstrate that PSB-0739 is the most potent competitive nonnucleotide antagonist at the human P2Y 12 receptor described so far. The results also indicate that the sulfonic acid residue at ring D is involved in the interaction of antagonists derived from reactive blue 2 with the residue Arg256 of the human P2Y 12 receptor.

Original languageEnglish
Pages (from-to)648-655
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume331
Issue number2
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Cibacron Blue F 3GA
Blood Platelets
Sulfonic Acids
Response Elements
Luciferases
Amino Acid Receptors
Anthraquinones
Colforsin
Cricetulus
Platelet Aggregation
Inhibitory Concentration 50
Ovary

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor. / Hoffmann, Kristina; Baqi, Younis; Morena, María Sol; Glänzel, Markus; Müller, Christa E.; Von Kügelgen, Ivar.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 331, No. 2, 11.2009, p. 648-655.

Research output: Contribution to journalArticle

Hoffmann, Kristina ; Baqi, Younis ; Morena, María Sol ; Glänzel, Markus ; Müller, Christa E. ; Von Kügelgen, Ivar. / Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor. In: Journal of Pharmacology and Experimental Therapeutics. 2009 ; Vol. 331, No. 2. pp. 648-655.
@article{fc3d09a6c8df458ba03cb4cf1a1dc046,
title = "Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor",
abstract = "The P2Y12 receptor plays a crucial role in platelet aggregation. In the present study, we analyzed the properties of non-nucleotide antagonists at the recombinant human P2Y12 receptor and searched for amino acids involved in the molecular interaction. Receptor function was assessed by measuring the cAMP response element (CRE)-directed luciferase expression in Chinese hamster ovary cells. The cellular cAMP production was accelerated by forskolin; 2-methylthio-ADP was used to activate the wild-type P2Y12 receptor or mutant constructs. 2-Methylthio-ADP inhibited the CRE-dependent luciferase expression with an IC50 value of approximately 1 nM. The anthraquinone derivative reactive blue 2 used at increasing concentrations shifted the concentration-response curve of 2-methylthio-ADP to the right in a manner compatible with competitive antagonism (pA2 value, 7.4). Its analog, 1-amino-4-[4-phenylamino-3-sulfophenylamino]-9,10-dioxo-9,10- dihydroanthracene-2-sulfonate (PSB-0739), showed a markedly higher antagonistic potency with a pA2 value of 9.8. In cells expressing the R256A-mutant receptor, the potencies of both reactive blue 2 (apparent pKB, 5.9) and PSB-0739 (apparent pKB, 9.1) were decreased. The same was true for the pure reactive blue 2 meta- and para-isomers and for the ortho-isomer cibacron blue 3GA. In contrast, the analog, 1-amino-4-[4-anilino-phenylamino]-9, 10-dioxo-9,10-dihydroanthracene-2-sulfonate, lacking a sulfonic acid residue at ring D (PSB-0826), showed similar pKB values at wild-type (8.4) and R256A-mutant receptors (8.3). In summary, the results demonstrate that PSB-0739 is the most potent competitive nonnucleotide antagonist at the human P2Y 12 receptor described so far. The results also indicate that the sulfonic acid residue at ring D is involved in the interaction of antagonists derived from reactive blue 2 with the residue Arg256 of the human P2Y 12 receptor.",
author = "Kristina Hoffmann and Younis Baqi and Morena, {Mar{\'i}a Sol} and Markus Gl{\"a}nzel and M{\"u}ller, {Christa E.} and {Von K{\"u}gelgen}, Ivar",
year = "2009",
month = "11",
doi = "10.1124/jpet.109.156687",
language = "English",
volume = "331",
pages = "648--655",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor

AU - Hoffmann, Kristina

AU - Baqi, Younis

AU - Morena, María Sol

AU - Glänzel, Markus

AU - Müller, Christa E.

AU - Von Kügelgen, Ivar

PY - 2009/11

Y1 - 2009/11

N2 - The P2Y12 receptor plays a crucial role in platelet aggregation. In the present study, we analyzed the properties of non-nucleotide antagonists at the recombinant human P2Y12 receptor and searched for amino acids involved in the molecular interaction. Receptor function was assessed by measuring the cAMP response element (CRE)-directed luciferase expression in Chinese hamster ovary cells. The cellular cAMP production was accelerated by forskolin; 2-methylthio-ADP was used to activate the wild-type P2Y12 receptor or mutant constructs. 2-Methylthio-ADP inhibited the CRE-dependent luciferase expression with an IC50 value of approximately 1 nM. The anthraquinone derivative reactive blue 2 used at increasing concentrations shifted the concentration-response curve of 2-methylthio-ADP to the right in a manner compatible with competitive antagonism (pA2 value, 7.4). Its analog, 1-amino-4-[4-phenylamino-3-sulfophenylamino]-9,10-dioxo-9,10- dihydroanthracene-2-sulfonate (PSB-0739), showed a markedly higher antagonistic potency with a pA2 value of 9.8. In cells expressing the R256A-mutant receptor, the potencies of both reactive blue 2 (apparent pKB, 5.9) and PSB-0739 (apparent pKB, 9.1) were decreased. The same was true for the pure reactive blue 2 meta- and para-isomers and for the ortho-isomer cibacron blue 3GA. In contrast, the analog, 1-amino-4-[4-anilino-phenylamino]-9, 10-dioxo-9,10-dihydroanthracene-2-sulfonate, lacking a sulfonic acid residue at ring D (PSB-0826), showed similar pKB values at wild-type (8.4) and R256A-mutant receptors (8.3). In summary, the results demonstrate that PSB-0739 is the most potent competitive nonnucleotide antagonist at the human P2Y 12 receptor described so far. The results also indicate that the sulfonic acid residue at ring D is involved in the interaction of antagonists derived from reactive blue 2 with the residue Arg256 of the human P2Y 12 receptor.

AB - The P2Y12 receptor plays a crucial role in platelet aggregation. In the present study, we analyzed the properties of non-nucleotide antagonists at the recombinant human P2Y12 receptor and searched for amino acids involved in the molecular interaction. Receptor function was assessed by measuring the cAMP response element (CRE)-directed luciferase expression in Chinese hamster ovary cells. The cellular cAMP production was accelerated by forskolin; 2-methylthio-ADP was used to activate the wild-type P2Y12 receptor or mutant constructs. 2-Methylthio-ADP inhibited the CRE-dependent luciferase expression with an IC50 value of approximately 1 nM. The anthraquinone derivative reactive blue 2 used at increasing concentrations shifted the concentration-response curve of 2-methylthio-ADP to the right in a manner compatible with competitive antagonism (pA2 value, 7.4). Its analog, 1-amino-4-[4-phenylamino-3-sulfophenylamino]-9,10-dioxo-9,10- dihydroanthracene-2-sulfonate (PSB-0739), showed a markedly higher antagonistic potency with a pA2 value of 9.8. In cells expressing the R256A-mutant receptor, the potencies of both reactive blue 2 (apparent pKB, 5.9) and PSB-0739 (apparent pKB, 9.1) were decreased. The same was true for the pure reactive blue 2 meta- and para-isomers and for the ortho-isomer cibacron blue 3GA. In contrast, the analog, 1-amino-4-[4-anilino-phenylamino]-9, 10-dioxo-9,10-dihydroanthracene-2-sulfonate, lacking a sulfonic acid residue at ring D (PSB-0826), showed similar pKB values at wild-type (8.4) and R256A-mutant receptors (8.3). In summary, the results demonstrate that PSB-0739 is the most potent competitive nonnucleotide antagonist at the human P2Y 12 receptor described so far. The results also indicate that the sulfonic acid residue at ring D is involved in the interaction of antagonists derived from reactive blue 2 with the residue Arg256 of the human P2Y 12 receptor.

UR - http://www.scopus.com/inward/record.url?scp=70350449259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350449259&partnerID=8YFLogxK

U2 - 10.1124/jpet.109.156687

DO - 10.1124/jpet.109.156687

M3 - Article

C2 - 19690189

AN - SCOPUS:70350449259

VL - 331

SP - 648

EP - 655

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -